Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benefix Safety and Efficacy in Chinese Hemophilia B Patients
NCT02336178Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jan 2015
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of coagulation factor ix recombinant in hemophilia B (HB), sponsored by Pfizer. Primary endpoints: Percentage of Participants Who Developed Factor IX Inhibitor up to 6 months, Number of Participants With Allergic Reactions up to 6 months and 1 more. Started Jan 2015; status: completed.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT02336178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336178.